CHE Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
CHE is not a good buy right now for a beginner long-term investor with $50,000-$100,000 available. The stock is in a strong uptrend, but it is already extended and overbought, so the current entry is not attractive for someone who is impatient and wants to buy now. I would wait for a pullback or a better risk-adjusted entry rather than chase the move.
CHE shows a bullish trend technically: MACD histogram is positive and expanding, and the moving averages are aligned bullishly with SMA_5 > SMA_20 > SMA_200. However, RSI_6 is extremely overbought at 89.721, which suggests the recent rally may be stretched in the short term. Price at 489 is near resistance at 483.868 and below R2 at 499.015, so upside from here is limited without a fresh consolidation. Overall trend is strong, but the stock looks extended rather than ideally buyable right now.
Recent news is mildly positive because Chemed confirmed its Q2 2026 earnings release date and conference call, which keeps attention on the upcoming catalyst. Analyst commentary was constructive after a solid Q1 print and a rare post-Q1 guidance raise, with VITAS showing strong census growth and margin outperformance. The stock also has a strong technical trend and bullish options sentiment. The similarity-based trend data suggests positive follow-through over the next week and month.
The main negative factor is that the stock is technically overbought, which makes the current level less appealing for immediate long-term entry. Hedge funds are selling, and that selling has increased 158.47% over the last quarter. No recent insider accumulation was reported, and there is no congress trading support. Analyst rating remains only Sector Perform, which is not a strong outright bullish endorsement.
No detailed financial snapshot was available, so the latest quarter cannot be fully quantified here. The available earnings-related commentary indicates a strong Q1 2026 season, with VITAS delivering strong census growth and margin outperformance that drove consolidated EBITDA and EPS well above consensus. Management also raised guidance after Q1, which is a positive sign of underlying operating momentum. The next reported quarter will be Q2 2026, with results due July 28, 2026.
RBC Capital raised its price target on CHE to $436 from $422 and kept a Sector Perform rating. The tone was positive on recent execution, especially after a strong Q1 and guidance raise, but the rating itself is still neutral. Wall Street’s pro view is that Chemed is executing well operationally, while the con view is that the stock still lacks a strong consensus Buy rating and has already rallied sharply.
